{"id":"vehicle-topical-foam","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a vehicle or excipient formulation, this foam serves as a delivery system rather than having its own therapeutic mechanism. It is designed to provide optimal skin penetration, retention, and cosmetic acceptability for topical medications. The foam format enhances spreadability and patient compliance compared to other topical delivery forms.","oneSentence":"Vehicle Topical Foam is an inert formulation base designed to deliver active pharmaceutical ingredients to the skin surface.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:40:27.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Topical delivery vehicle for dermatological agents"}]},"trialDetails":[{"nctId":"NCT05185258","phase":"PHASE4","title":"Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-02-16","conditions":"Psoriasis Vulgaris, Psoriasis, Skin Diseases","enrollment":12},{"nctId":"NCT07184645","phase":"PHASE3","title":"A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2025-09","conditions":"Atopic Dermatitis (AD)","enrollment":198},{"nctId":"NCT07173478","phase":"PHASE3","title":"A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2025-10","conditions":"Atopic Dermatitis (AD)","enrollment":156},{"nctId":"NCT05028582","phase":"PHASE3","title":"Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-08-24","conditions":"Scalp Psoriasis","enrollment":432},{"nctId":"NCT02416258","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Skin and Connective Tissue Diseases","enrollment":50},{"nctId":"NCT03943407","phase":"NA","title":"Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch","status":"WITHDRAWN","sponsor":"Aalborg University","startDate":"2019-11-01","conditions":"Itch","enrollment":""},{"nctId":"NCT04973228","phase":"PHASE3","title":"Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-07-08","conditions":"Seborrheic Dermatitis","enrollment":457},{"nctId":"NCT04960930","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Minocycline Hydrochloride Foam in the Treatment of Moderate-to-severe Acne Vulgaris","status":"COMPLETED","sponsor":"Cutia Therapeutics (Shanghai) Co., Ltd","startDate":"2021-09-17","conditions":"Acne Vulgaris","enrollment":372},{"nctId":"NCT04091646","phase":"PHASE2","title":"Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-04","conditions":"Seborrheic Dermatitis","enrollment":226},{"nctId":"NCT01555463","phase":"PHASE3","title":"Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-09","conditions":"Papulopustular Rosacea","enrollment":961},{"nctId":"NCT02094716","phase":"PHASE2","title":"A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-04","conditions":"Scabies","enrollment":130},{"nctId":"NCT02815267","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2016-05","conditions":"Acne Vulgaris","enrollment":466},{"nctId":"NCT03271021","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-07-17","conditions":"Acne Vulgaris","enrollment":1488},{"nctId":"NCT02815280","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2016-05","conditions":"Acne Vulgaris","enrollment":495},{"nctId":"NCT04104685","phase":"PHASE2","title":"A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2019-09-18","conditions":"Acne Vulgaris","enrollment":446},{"nctId":"NCT03142451","phase":"PHASE3","title":"A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-06-02","conditions":"Facial Papulopustular Rosacea","enrollment":751},{"nctId":"NCT03506477","phase":"PHASE4","title":"Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2018-05-21","conditions":"Plaque Psoriasis, Psoriasis","enrollment":25},{"nctId":"NCT04608500","phase":"PHASE3","title":"A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2017-06-01","conditions":"Facial Papulopustular Rosacea","enrollment":771},{"nctId":"NCT04571151","phase":"PHASE4","title":"Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis","status":"UNKNOWN","sponsor":"Skin Sciences, PLLC","startDate":"2021-01","conditions":"Plaque Psoriasis","enrollment":30},{"nctId":"NCT02899962","phase":"PHASE3","title":"LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-02-15","conditions":"Psoriasis Vulgaris","enrollment":722},{"nctId":"NCT00617903","phase":"PHASE2","title":"Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2008-01","conditions":"Papulopustular Rosacea","enrollment":83},{"nctId":"NCT01430312","phase":"PHASE1","title":"21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT01430533","phase":"PHASE1","title":"Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-09","conditions":"Healthy","enrollment":240},{"nctId":"NCT03287791","phase":"PHASE3","title":"A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-07-19","conditions":"Rosacea","enrollment":924},{"nctId":"NCT03689010","phase":"PHASE1","title":"To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2017-12-12","conditions":"Rosacea","enrollment":1116},{"nctId":"NCT02368210","phase":"PHASE3","title":"A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2015-01","conditions":"Plaque Psoriasis","enrollment":151},{"nctId":"NCT02742441","phase":"PHASE3","title":"A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2016-06","conditions":"Plaque Psoriasis","enrollment":409},{"nctId":"NCT00842153","phase":"PHASE4","title":"Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2007-11","conditions":"Psoriasis","enrollment":58},{"nctId":"NCT02601963","phase":"PHASE2","title":"Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2015-09","conditions":"Rosacea, Papulopustular Rosacea","enrollment":233},{"nctId":"NCT01226459","phase":"PHASE3","title":"Clinical Trial in Females for Female Pattern Hair Loss","status":"COMPLETED","sponsor":"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","startDate":"2010-09","conditions":"Androgenetic Alopecia","enrollment":404},{"nctId":"NCT01826461","phase":"PHASE2","title":"An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"PreCision Dermatology, Inc.","startDate":"2013-03","conditions":"Atopic Dermatitis","enrollment":151},{"nctId":"NCT01319370","phase":"PHASE2","title":"Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia","status":"COMPLETED","sponsor":"Natalie GARCIA BARTELS","startDate":"2010-11","conditions":"Androgenetic Alopecia","enrollment":70},{"nctId":"NCT00768599","phase":"PHASE2","title":"A Study of Econazole Foam 1% in Athlete's Foot","status":"COMPLETED","sponsor":"AmDerma","startDate":"2008-03","conditions":"Tinea Pedis, Athlete's Foot","enrollment":135}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vehicle Control (Placebo)"],"phase":"phase_3","status":"active","brandName":"Vehicle Topical Foam","genericName":"Vehicle Topical Foam","companyName":"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.","companyId":"johnson-johnson-healthcare-products-division-of-mcneil-ppc-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vehicle Topical Foam is an inert formulation base designed to deliver active pharmaceutical ingredients to the skin surface. Used for Topical delivery vehicle for dermatological agents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}